Allogene Therapeutics, Inc. — Form 8-K Summary
Business context and reporting period
Allogene Therapeutics, Inc. filed this Form 8-K on June 14, 2023, reporting an executive officer change occurring on June 9, 2023. The filing does not present quarterly or annual financial results.
Key financial metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material changes versus the prior comparable period
- Eric Schmidt, Ph.D., notified the company of his resignation as Chief Financial Officer, principal financial officer, and principal accounting officer.
- His resignation is effective at the close of business on August 2, 2023.
- Mr. Schmidt stated that he is resigning to spend more time with his family.
- The company has initiated a search for his replacement.
Guidance, outlook, risks, contingencies, and unusual items
The filing provides no financial guidance or operating outlook. The executive transition may create temporary disruption or control and reporting risks, although the filing does not identify any specific adverse financial impact or accounting issues.
Investor verification priorities
- Verify the appointment, qualifications, and start date of the successor CFO.
- Review subsequent filings for any changes to the effective resignation date or interim finance leadership arrangements.
- Assess subsequent financial filings for disclosures regarding reporting controls, liquidity, financing needs, or impacts from the CFO transition.